Pictet North America Advisors’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
FP
TP
Pictet North America Advisors's MRNA Position: Q3 2023 in Review
Pictet North America Advisors sold out of Moderna (MRNA) in Q3 2023, closing a stake of 5,430 shares — an estimated $660K sold.
Pictet North America Advisors first reported a position in MRNA in Q1 2023 and held it in 2 quarters. The position peaked at $813K in Q1 2023. 890 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.
- Pictet North America Advisors reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
- Pictet North America Advisors sold 5,430 Moderna shares in Q3 2023, an estimated $660K.
- Pictet North America Advisors first reported a position in Moderna in Q1 2023 and held it in 2 quarters.
- Pictet North America Advisors's Moderna position peaked at $813K in Q1 2023.
- 890 funds tracked by Wall St. Rank held Moderna as of Q3 2023.
Based on Pictet North America Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.